Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 22 01:36PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.92 Insider Own2.88% Shs Outstand191.38M Perf Week3.21%
Market Cap265.91M Forward P/E- EPS next Y-0.63 Insider Trans-2.62% Shs Float178.72M Perf Month32.57%
Income-175.84M PEG- EPS next Q-0.18 Inst Own58.55% Short Float2.26% Perf Quarter16.53%
Sales90.17M P/S2.95 EPS this Y49.31% Inst Trans-4.28% Short Ratio2.05 Perf Half Y170.19%
Book/sh0.69 P/B2.09 EPS next Y14.06% ROA-36.72% Short Interest4.05M Perf Year162.73%
Cash/sh1.57 P/C0.92 EPS next 5Y-7.30% ROE-95.68% 52W Range0.41 - 1.93 Perf YTD155.75%
Dividend Est.- P/FCF- EPS past 5Y- ROI-51.83% 52W High-25.05% Beta0.66
Dividend TTM- Quick Ratio5.79 Sales past 5Y-20.42% Gross Margin60.91% 52W Low250.22% ATR (14)0.13
Dividend Ex-Date- Current Ratio6.10 EPS Y/Y TTM58.37% Oper. Margin-147.13% RSI (14)58.06 Volatility9.25% 11.05%
Employees137 Debt/Eq1.83 Sales Y/Y TTM1.51% Profit Margin-195.02% Recom3.40 Target Price1.80
Option/ShortYes / Yes LT Debt/Eq1.68 EPS Q/Q73.95% Payout- Rel Volume0.55 Prev Close1.39
Sales Surprise41.05% EPS Surprise0.00% Sales Q/Q0.21% EarningsMay 09 AMC Avg Volume1.98M Price1.45
SMA2013.40% SMA503.58% SMA20059.73% Trades Volume710,310 Change3.96%
Date Action Analyst Rating Change Price Target Change
Jun-28-24Initiated Rodman & Renshaw Buy $2
Nov-20-23Resumed JP Morgan Underweight
Nov-09-23Upgrade TD Cowen Market Perform → Outperform
May-10-23Upgrade Jefferies Underperform → Hold $1.50 → $1
Feb-24-23Downgrade Jefferies Hold → Underperform $3.20 → $1.50
Aug-08-22Downgrade JP Morgan Neutral → Underweight
May-31-22Resumed Jefferies Hold $12 → $4
Apr-18-22Downgrade Goldman Neutral → Sell $3
Mar-15-22Downgrade Mizuho Buy → Neutral $35 → $8
Mar-15-22Downgrade Cowen Outperform → Market Perform
Jun-12-24 09:30AM
May-30-24 06:00PM
May-10-24 04:41PM
10:35AM Loading…
May-09-24 05:39PM
May-02-24 06:00PM
Apr-03-24 11:30AM
Mar-25-24 10:00AM
Mar-22-24 02:00PM
Mar-06-24 12:33PM
Mar-05-24 10:07AM
09:00AM Loading…
Mar-04-24 05:30PM
Feb-27-24 06:00PM
Feb-26-24 06:00PM
Feb-20-24 10:00AM
Jan-03-24 06:00PM
Dec-11-23 06:00PM
Dec-07-23 11:31AM
Nov-09-23 08:39AM
Nov-08-23 11:47AM
05:28PM Loading…
Nov-07-23 05:28PM
Oct-31-23 06:00PM
Oct-26-23 10:02AM
Oct-23-23 10:08AM
Oct-13-23 08:30AM
Oct-02-23 09:00AM
Sep-27-23 09:00AM
Sep-14-23 07:54AM
Sep-13-23 09:00AM
Sep-07-23 11:31AM
Sep-06-23 06:00PM
Aug-17-23 07:02PM
Aug-09-23 09:25AM
Aug-08-23 05:30PM
Aug-07-23 10:23AM
Aug-01-23 06:00PM
Jul-24-23 03:48AM
Jul-16-23 08:49AM
Jun-12-23 06:00PM
Jun-08-23 12:55PM
May-10-23 11:28AM
May-09-23 06:45PM
May-08-23 09:29AM
May-04-23 10:00AM
May-02-23 10:01AM
Apr-27-23 08:30AM
Apr-19-23 08:38AM
Apr-17-23 05:00PM
Apr-16-23 06:30AM
Apr-13-23 10:59AM
Apr-11-23 08:57AM
Apr-10-23 10:07AM
Apr-02-23 08:27AM
Mar-30-23 11:30AM
Mar-29-23 05:44PM
Mar-24-23 12:00PM
Mar-22-23 09:35AM
Mar-14-23 03:43AM
Feb-28-23 05:15PM
Feb-24-23 10:23AM
Feb-23-23 06:20PM
Jan-09-23 09:04AM
Jan-04-23 09:00AM
Dec-12-22 10:05AM
Dec-05-22 08:00AM
Nov-10-22 09:05AM
Nov-09-22 09:00AM
Nov-04-22 12:35PM
Nov-03-22 06:35PM
Oct-28-22 10:00AM
Oct-27-22 10:02AM
Oct-25-22 06:00PM
Oct-24-22 07:55AM
Oct-11-22 05:13PM
Oct-07-22 03:42PM
Sep-07-22 01:15AM
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CHESS ROBERTDirectorJun 14 '24Sale1.2019,50023,400255,273Jun 14 06:02 PM
ROBIN HOWARD WPresident & CEOMay 17 '24Sale1.7516,65029,138863,239May 20 09:14 PM
Zalevsky JonathanChief R&D OfficerMay 17 '24Sale1.757,35512,871257,670May 20 09:13 PM
Wilson Mark AndrewChief Legal OfficerMay 17 '24Sale1.756,26010,955230,414May 20 09:12 PM
Deep Track Capital, LP10% OwnerMay 10 '24Sale1.7856,00099,63018,344,000May 13 04:36 PM
ROBIN HOWARD WPresident & CEOFeb 20 '24Sale0.6820,03313,622879,889Feb 22 08:16 PM
Zalevsky JonathanChief R&D OfficerFeb 20 '24Sale0.689,0146,130265,025Feb 22 08:19 PM
Wilson Mark AndrewChief Legal OfficerFeb 20 '24Sale0.687,6065,172236,674Feb 22 08:17 PM
ROBIN HOWARD WPresident & CEONov 17 '23Sale0.4919,8779,740899,922Nov 20 08:58 PM
Zalevsky JonathanChief R&D OfficerNov 17 '23Sale0.499,6464,727274,039Nov 20 09:02 PM
Wilson Mark AndrewChief Legal OfficerNov 17 '23Sale0.497,1793,518243,780Nov 20 09:00 PM
Curet MyriamDirectorSep 18 '23Sale0.694,3593,00827,418Sep 20 08:09 PM
Ajer Jeffrey RobertDirectorSep 18 '23Sale0.694,3593,00834,153Sep 20 08:06 PM
ROBIN HOWARD WPresident & CEOAug 16 '23Sale0.7819,99815,598919,799Aug 17 08:06 PM
Zalevsky JonathanChief R&D OfficerAug 16 '23Sale0.789,7037,568283,685Aug 17 08:08 PM
Wilson Mark AndrewChief Legal OfficerAug 16 '23Sale0.787,2215,632250,959Aug 17 08:07 PM